Literature DB >> 21520922

Comparative biophysical studies of sartan class drug molecules losartan and candesartan (CV-11974) with membrane bilayers.

Charalambos Fotakis1, Dionysios Christodouleas, Panagiotis Zoumpoulakis, Eftichia Kritsi, Nikolas-Ploutarch Benetis, Thomas Mavromoustakos, Heribert Reis, Argiro Gili, Manthos G Papadopoulos, Maria Zervou.   

Abstract

The interactions of the antihypertensive AT(1) antagonists candesartan and losartan with membrane bilayers were studied through the application of DSC, Raman, and solid state (31)P NMR spectroscopies. (1)H and (13)C NMR resonances of candesartan were assigned on the basis of 1D and 2D NMR spectroscopy. A (31)P CP NMR broadline fitting methodology in combination with ab initio computations was implemented and, in conjunction with DSC and Raman results, provided valuable information regarding the perturbation, localization, orientation, and dynamic properties of the drugs in membrane models. In particular, results indicate that losartan anchors in the mesophase region of the lipid bilayers with the tetrazole group oriented toward the polar headgroup, whereas candesartan has less definite localization spanning from water interface toward the mesophase and upper segment of the hydrophobic region. Both sartan molecules decrease the mobilization of the phospholipids alkyl chains. Losartan exerts stronger interactions compared with candesartan, as depicted by the more prominent thermal, structural, and dipolar (1)H-(31)P changes that are caused in the lipid bilayers. At higher concentrations, candesartan strengthens the polar interactions and induces increased order at the bilayer surface. At the highest concentration used (20 mol %), only losartan induces formation of microdomains attributed to the flexibility of its alkyl chain. These results in correlation to reported data with other AT(1) antagonists strengthen the hypothesis that this class of molecules may approach the active site of the receptor by insertion in the lipid core, followed by lateral diffusion toward the binding site. Further, the similarities and differences of these drugs in their interactions with lipid bilayers establish, at least in part, their pharmacological properties.
© 2011 American Chemical Society

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21520922     DOI: 10.1021/jp110371k

Source DB:  PubMed          Journal:  J Phys Chem B        ISSN: 1520-5207            Impact factor:   2.991


  8 in total

Review 1.  Link between a high k on for drug binding and a fast clinical action: to be or not to be?

Authors:  Georges Vauquelin
Journal:  Medchemcomm       Date:  2018-08-16       Impact factor: 3.597

2.  Effects of target binding kinetics on in vivo drug efficacy: koff , kon and rebinding.

Authors:  Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2016-07-04       Impact factor: 8.739

Review 3.  Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo.

Authors:  Georges Vauquelin
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

4.  Experimental and DFT characterization, antioxidant and anticancer activities of a Cu(II)-irbesartan complex: structure-antihypertensive activity relationships in Cu(II)-sartan complexes.

Authors:  María S Islas; Alicia Luengo; Carlos A Franca; Mercedes Griera Merino; Laura Calleros; Manuel Rodriguez-Puyol; Luis Lezama; Evelina G Ferrer; Patricia A M Williams
Journal:  J Biol Inorg Chem       Date:  2016-08-09       Impact factor: 3.358

5.  The application of solid-state NMR spectroscopy to study candesartan cilexetil (TCV-116) membrane interactions. Comparative study with the AT1R antagonist drug olmesartan.

Authors:  Dimitrios Ntountaniotis; Tahsin Kellici; Andreas Tzakos; Pinelopi Kolokotroni; Theodore Tselios; Johanna Becker-Baldus; Clemens Glaubitz; Sonyan Lin; Alexandros Makriyannis; Thomas Mavromoustakos
Journal:  Biochim Biophys Acta       Date:  2014-06-16

6.  Effects of Cholesterol on the Partitioning of a Drug Molecule in Lipid Bilayers.

Authors:  Yuqin Yang; Hao Dong; Huan-Xiang Zhou
Journal:  J Phys Chem B       Date:  2021-05-13       Impact factor: 3.466

7.  Comparison of the GPVI inhibitors losartan and honokiol.

Authors:  Marie-Blanche Onselaer; Magdolna Nagy; Chiara Pallini; Jeremy A Pike; Gina Perrella; Lourdes Garcia Quintanilla; Johannes A Eble; Natalie S Poulter; Johan W M Heemskerk; Steve P Watson
Journal:  Platelets       Date:  2019-03-08       Impact factor: 3.862

Review 8.  On the Rational Drug Design for Hypertension through NMR Spectroscopy.

Authors:  Eleni Chontzopoulou; Andreas G Tzakos; Thomas Mavromoustakos
Journal:  Molecules       Date:  2020-12-22       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.